Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

GC 1130A

Next Previous
Drug Profile

GC 1130A

Alternative Names: GC-1130A; NP-3011; Recombinant human heparan N-sulfatase - GC Biopharma; rhHNS

Latest Information Update: 18 Feb 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GC Pharma
  • Developer GC Biopharma
  • Class Enzymes; Recombinant proteins
  • Mechanism of Action N-sulfoglucosamine sulfohydrolase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Mucopolysaccharidosis III
  • New Molecular Entity Yes
  • Available For Licensing Yes - Mucopolysaccharidosis III

Highest Development Phases

  • Phase I Mucopolysaccharidosis III

Most Recent Events

  • 11 Feb 2025 Pharmacodynamics data from preclinical studies in Mucopolysaccharidosis III
  • 31 Oct 2024 Phase-I clinical trials in Mucopolysaccharidosis III (In children) in Japan (Intracerebral) (NCT06567769)
  • 31 Oct 2024 Phase-I clinical trials in Mucopolysaccharidosis III (In children) in South Korea (Intracerebral) (NCT06567769)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top